Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14043611 | 0.98 | KCNH2 (0.56) | KCNH2TLR8PDPK1HRH3HRH2 | |
| SCHEMBL5748930 | 0.98 | KCNH2 (0.56) | KCNH2TLR8PDPK1HRH3HRH2 | |
| SCHEMBL5749599 | 0.98 | KCNH2 (0.56) | KCNH2TLR8PDPK1HRH3HRH2 | |
| SCHEMBL5748502 | 0.98 | KCNH2 (0.56) | KCNH2TLR8PDPK1HRH3HRH2 | |
| SCHEMBL12514073 | 0.94 | TLR8 (0.53) | KCNH2TLR8PDPK1HRH3HRH2 | |
| SCHEMBL12336950 | 0.86 | TLR8 (0.47) | TLR8PDPK1HRH3NOS2HRH4 | |
| SCHEMBL28749703 | 0.81 | HRH3 (0.51) | TLR8PDPK1HRH3HRH4NUDT1 | |
| SCHEMBL11561943 | 0.79 | KCNH2 (0.55) | KCNH2TLR8PDPK1NOS2KDM4E | |
| SCHEMBL899234 | 0.79 | KCNH2 (0.55) | KCNH2TLR8PDPK1KDM4E | |
| Ammonia Solution, Strong SCHEMBL5846083 | 0.79 | HRH3 (0.50) | TLR8PDPK1HRH3HRH4NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4914077-A | GOOD HUE AND STABILITY | EASTMAN KODAK COMPANY (US) | 1990-04-03 | — | — | US | claimed |
| US-11608384-B2 | Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2023-03-21 | — | — | US | disclosed |
| US-20220411407-A1 | ARYL AMINOPYRIMIDINES AS DUAL MERTK AND TYRO3 INHIBITORS AND METHODS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2022-12-29 | — | — | US | disclosed |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-25 | — | — | US | disclosed |
| CN-106687114-B | Pyrimidine compounds and methods of use thereof | 尤马治疗公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210198377-A1 | TPBG ANTIBODY AND PREPARATION METHOD THEREFOR, CONJUGATE AND USE THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2021-07-01 | — | — | US | disclosed |
| WO-2021097326-A1 | ARYL AMINOPYRIMIDINES AS DUAL MERTK AND TYRO3 INHIBITORS AND METHODS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200062856-A1 | Humanized Anti-TPBG Antibody, Preparation Method Therefor, Conjugate Thereof, and Applications | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3608335-A1 | HUMANIZED ANTI-TPBG ANTIBODY, PREPARATION METHOD THEREFOR, CONJUGATE THEREOF, AND APPLICATIONS | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
| CN-101421250-A | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them | EXELIXIS INC (US) | 2009-04-29 | — | — | CN | disclosed |
| CN-101302203-A | 6-aryl aminopyrimidine compound and synthetic method thereof | UNIV YUNNAN (CN) | 2008-11-12 | — | — | CN | disclosed |
| WO-2008130944-A1 | SOLID PHASE SYNTHESES OF AMINO PYRIMIDINE COMPOUNDS | IRM LLC (BM) | 2008-10-30 | — | — | WO | disclosed |
| CN-101242843-A | Aminopyrimidines as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| CN-101242844-A | Aminopyrimidines as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| CN-1130358-C | Imidazole compound and preparation method and application thereof | SMITHKLINE BEECHAM CORP (US) | 2003-12-10 | — | — | CN | disclosed |
| CN-1192147-A | Imidazole compounds | SMITHKLINE BEECHAM CORP (US) | 1998-09-02 | — | — | CN | disclosed |
| US-5795905-A | 3-AMINO-5-PHENYL-1,2,4-TRIAZOLES | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0846108-A1 | AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1996039400-A1 | AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198377-A1 | TPBG ANTIBODY AND PREPARATION METHOD THEREFOR, CONJUGATE AND USE THEREOF | TNFSF11, FARSB, SHBG | KCNH2 3451/4885TLR8 3397/4885PDPK1 4172/4885 |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSF1, HSPH1 | KCNH2 2363/4885TLR8 4230/4885PDPK1 2514/4885 |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | KCNH2 2926/4885TLR8 4349/4885PDPK1 3135/4885 |
| US-11608384-B2 | Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications | SHBG, IGSF11, CYP4F11 | KCNH2 4218/4885TLR8 2270/4885PDPK1 4404/4885 |
| US-20200062856-A1 | Humanized Anti-TPBG Antibody, Preparation Method Therefor, Conjugate Thereof, and Applications | SHBG, IGSF11, CYP4F11 | KCNH2 4218/4885TLR8 2270/4885PDPK1 4404/4885 |
| US-20220411407-A1 | ARYL AMINOPYRIMIDINES AS DUAL MERTK AND TYRO3 INHIBITORS AND METHODS THEREOF | MERTK, TYRO3, MATK | KCNH2 4815/4885TLR8 798/4885PDPK1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.